[21]Kharfan-Dabaja MA,Labopin M,Polge E,et of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse[J].JAMAOncol,2018,4(9)::10.1001/

[22]Mo XD,Zhang XH,Xu LP,et Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation:Results of a Registry Study[J].Biol Blood Marrow Transplant,2017,23(8)::10.1016/

[23]Mo X,Zhang X,Xu L,et salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation[J].Front Med,2019,13(2)::10.1007/s-017-0599-3.

[24]Chen H,Liu KY,Xu LP,et of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia[J].J Hematol Oncol,2012,5:29.DOI:10.1186/1756-8722-5-29.

[25]Pfeifer H,Wassmann B,Bethge W,et comparison of prophylactic and minimal residual disease-triggered imatinib afterallogeneic stem celltransplantation forBCR-ABL1-positive acute lymphoblastic leukemia[J].Leukemia,2013,27(6)::10.1038/

[26]Nishiwaki S,Imai K,Mizuta S,et of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL:a study from the adult ALLWG ofthe JSHCT[J].Bone MarrowTransplant,2016,51(1)::10.1038/

[27]Zhang FH,Ling YW,Zhai X,et al.The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia[J].Hematology,2013,18(3)::10.1179/Y..

[28]Liu H,Xuan L,Lin R,et al.A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT:a prospective clinical cohort study[J].Leukemia,2020.DOI:10.1038/s-020-01090-4.

[29]Hirschbühl K,Labopin M,Houhou M,et thirdgeneration tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party[J].Bone Marrow Transplant,2020.DOI:10.1038/s-020-01173-x.

[30]Giebel S,Czyz A,Ottmann O,et al.Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia:A position statementofthe Acute Leukemia Working Partyofthe[J].Cancer,2016,122(19)::10.1002/cncr..

[31]Bazarbachi A,Bug G,Baron F,et practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication:a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation[J].Haematologica,2020.DOI:10.3324/.

[32]Burchert A,Bug G,Fritz LV,et Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid LeukemiaWithFLT3-Internal Tandem Duplication Mutation(SORMAIN)[J].J Clin Oncol,2020,38(26)::10.1200/

[33]Xuan L,Wang Y,Huang F,et maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation:an openlabel,multicentre,randomised phase 3 trial[J].Lancet Oncol,2020,21(9)::10.1016/S1470-2045(20)-1.

[34]Xuan L,Wang Y,Chen J,et Therapy Is Associated with ImprovedOutcomesfor FMS-likeTyrosineKinase3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation[J].Biol Blood Marrow Transplant,2019,25(8)::10.1016/

[35]Maziarz RT,Levis M,Patnaik MM,et after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia [J].Bone Marrow Transplant,2020.DOI:10.1038/s-020-01153-1.

[36]Craddock C,Jilani N,Siddique S,et and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial[J].Biol Blood Marrow Transplant,2016,22(2)::10.1016/

[37]Vij R,Le-Rademacher J,Laumann K,et al.A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia):Results of CALGB (Alliance)[J].Biol Blood Marrow Transplant,2019,25(10)::10.1016/

[38]Platzbecker U,Middeke JM,Sockel K,et residual disease-guided treatmentwith azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia(RELAZA2):an open-label,multicentre,phase 2 trial[J].Lancet Oncol,2018,19(12)::10.1016/s1470-2045(18)-1.

[39]Guillaume T,Malard F,Magro L,et phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusionsfollowing allogeneic hematopoietic stem cell transplantation forhigh-risk acute myeloid leukemia and myelodysplastic syndrome[J].Bone MarrowTransplant,2019,54(11)::10.1038/s-019-0536-y.

文章来源：《中国实验血液学杂志》 网址: http://www.zgsyxyxzz.cn/qikandaodu/2021/0508/635.html